From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...